Products
Ombitasvir was approved in the EU and many countries in 2014 in film-coated tablet form (Viekirax, combination drug).
Structure and properties
Ombitasvir (C50H67N7O8, Mr = 894.1 g/mol)
Effects
Ombitasvir (ATC J05AX66) has antiviral properties against HCV virus. The effects are due to binding to the viral protein NS5A (Non-Structural Protein 5A). Unlike other HCV antiviral drugs, the drug target is not an enzyme but a phosphoprotein that plays a role in RNA replication and assembly.
Indications
For the treatment of chronic hepatitis C (combination therapy).
